With 160 coronavirus vaccine candidates under development around the world, it's not surprising that we would get reports on three successful, if very early, trials today. The coronavirus vaccine that Oxford University is developing with AstraZeneca (AZN) showed increased levels of antibody production and increased T-cell activity in human trials according to results published today […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.
